A groundbreaking study by researchers at the University of Texas Medical Branch is shedding light on a promising development in the battle against highly fatal hemorrhagic diseases caused by orthoebolaviruses, including the notorious Ebola virus.
In the study, researchers focused on the development and efficacy of Obeldesivir (ODV), an oral antiviral drug of the parent nucleoside of remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. Laboratory tests revealed ODV's effectiveness against Ebola, Sudan virus, and Marburg virus.